Oppenheimer analyst Leah R. Cann maintained a Hold rating on Agios Pharma (NASDAQ: AGIO) today. The company’s shares closed yesterday at $86.20, close to its 52-week high of $89.33.
Cann said:
“On May 16, ASCO Abstract #2002 was released detailing preliminary clinical data for AG-881 from a phase I study in patients with advanced IDH-mutant solid tumors, including glioma. AG-881 is a promising early stage molecule. We have not included any impact from AG-881 in our outlook through 2021.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 15.8% and a 58.6% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $100.
See today’s analyst top recommended stocks >>
The company has a one-year high of $89.33 and a one-year low of $45.96. Currently, Agios Pharma has an average volume of 380.7K.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGIO in relation to earlier this year. Most recently, in February 2018, Kaye Foster-Cheek, a Director at AGIO bought 2,200 shares for a total of $104,126.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
